ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

NPIL invests in potent drugs

August 7, 2006 | APPEARED IN VOLUME 84, ISSUE 32

NPIL Pharma will expand its high-potency substances facility in Grangemouth, Scotland. The Indian firm, which bought the facility from Avecia in December 2005, says it will invest $500,000 and add 16 biochemists and other staffers in response to strong customer demand for cytotoxic pharmaceutical actives, in particular ones that are conjugated with monoclonal antibodies. NPIL says more than 20 of these immunoconjugates are in drug trials around the world.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment